J Korean Assoc Oral Maxillofac Surg.  2010 Feb;36(1):16-22. 10.5125/jkaoms.2010.36.1.16.

The effect of hyaluronic acid on anti-inflammatory action in mouse

• Kim SK
• Lee HS
• Byeon KS
• Lee YJ
• Hong SM
• Choi MR
• Park JW

• KMID: 1457814
• DOI: http://doi.org/10.5125/jkaoms.2010.36.1.16

Abstract

PURPOSE
The purpose of this study was not only to evaluate the relative mRNA expression of interleukin-1beta(IL-1beta), cyclooxygenase2 (COX-2) and prostaglandin E2 (PGE2) by RT-PCR analysis but to observe pattern of edema by light microscopic and electron microscope after topical apply of hyaluronic acid in inflammation-guided mouse. MATERIAL AND METHODS: Mice of this study were devided into 4 groups: Control group (no inflammation guided), Positive control (inflammation guided + vaselin apply), Protopic group (inflammation guided + protopic apply), Hyaluronic group (inflammation guided + hyaluronic acid apply).
RESULTS
Hyaluronic group showed less expressions of IL-1beta, COX-2, PGE2 than those of positive control & protopic group. Hyaluronic group revealed a decreased inflammation than positive control & protopic group in Light Microscope. Hyaluronic group appeared decreased edema of ear compare to positive control & protopic group in Elecron Microscope.
CONCLUSION
It was considered that hyaluronic acid has an antiinflammatory effect for intercepting the gene expression of cytokines related to inflammation.

Keyword

Hyaluronic acid; Anti-inflammatory agent; Mice

MeSH Terms

Animals
Cytokines
Dinoprostone
Ear
Edema
Electrons
Gene Expression
Hyaluronic Acid
Inflammation
Light
Mice
RNA, Messenger
Cytokines
Dinoprostone
Hyaluronic Acid
RNA, Messenger

Figure

• 

  Fig. 1. A. Photograph showing mouse with normal ear. B. Photograph showing mouse with inflammation induced ear. C. Photograph showing 0.2% hyaluronic gel (Gingigel®) which was used in this study. D. Photograph showing 0.1% tacrolimus ointment (Protopic oint®) which was used in this study.

• 

  Fig. 2. A. mRNA expression of IL-1β. B. T-test value of relative mRNA expression level of IL-1β. C. T-test value of relative mRNA expression level of COX2. D. T-test value of relative mRNA expression level of PGE2.

• 

  Fig. 3. A-C. Light microscopy showing lots of inflammatory cells and capillarys, protopic group, sagittal section and HE stain X 100. D-F. Light microscopy showing less inflammatory cells in hyaluronic group than in protopic group also showing reduction of sweat gland, hyaluronic group, sagittal section and HE stain × 100.

• 

  Fig. 4. A. Scanning electron microscopy showing size of ear tissue (14 × 20 um), control group, sagittal section × 1000. B. Scanning electron microscopy showing size of edematous ear tissue (22 × 30 um), protopic group, sagittal section × 1000. C. Scanning electron microscopy showing size of edematous ear tissue (16 × 22 um), hyaluronic group, sagittal section × 1000.

Reference

References

1. Altman RD, Moskowitz R. A randomized clinical trial of intra-articular sodium hyaluronate in patients with osteoarthritis of the knee: a summary. Am J Orthop (Belle Mead NJ). 1999; 28:3–4.

2. Caporossi A, Baiocchi S, Sforzi C, Frezzotti R. Healon GV versus Healon in demanding cataract surgery. J Cataract Refract Surg. 1995; 21:710–3.

3. Matsuno H, Yudoh K, Kondo M, Goto M, Kimura T. Bioche-mi-cal effect of intra-articular injections of high molecular weight hyaluronate in rheumatoid arthritis patients. Inflamm Res. 1999; 48:154–9.

4. Liguori V, Guillemin C, Pesce GF, Mirimanoff RO, Bernier J. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiother Oncol. 1997; 42:155–61.

5. Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford). 1999; 38:602–7.

6. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995; 3:213–25.

7. Kim HJ, Shin CH, Hong J, Choi JH. The effects of hyaluronic acid gel on the healing of oral mucosa. J Korean Assoc Oral Maxillofac Surg. 2007; 33:359–66.

8. Rosa DS, Aranha AC, Eduardo Cde P, Aoki A. Esthetictreatment of gingival melanin hyperpigmentation with Er:YAG laser: short-term clinical observations and patient follow-up. J. Periodontol. 2007; Oct. 78(10):2018–25.

9. Pradeep AR, Kumar MS, Ramachandraprasad MV, Shikha C. Gingival crevicular fluid levels of neopterin in healthy subjects and in patients with different periodontal diseases. J Periodontol. 2007; 78:1962–7.

10. Villa AA. Clinical, biochemical and histopatological correlacion in diabetic patiens with periodontal disease. Rev Fac Cien Med Univ Nac Cordoba. 2006; 63(2S):50–5.

11. Vangelisti R, Pagnacco O, Erra C. Hyaluronic acid in the topical treatment of gingival inflammations: preliminary clinical trial. Attualita Terapeutica Int. 1997; 15:2–3.

12. Pagnacco A, Vangelisti R, Erra C, Poma A. Double-blind clinical trial vs. placebo of a new sodium-hyaluronate-based gingival gel. Attualita Terapeutica Int. 1997; 15:1–7.

13. Rabasseda X. The role of hyaluronic acid in the management of periodontal disease. Drugs Today (Barc). 2000; 36(S):1–20.

14. Jentsch H, Pomowski R, Kundt G, Gocke R. Treatment of gingivitis with hyaluronan. J Clin Periodontol. 2003; 30:159–64.

15. Pistorius A, Martin M, Willershausen B, Rockmann P. The clinical application of hyaluronic acid in gingivitis therapy. Quintessence Int. 2005; 36:531–8.

16. Toole BP, Jackson G, Gross J. Hyaluronate in morphogenesis: inhibition of chondrogenesis in vitro. Proc Natl Acad Sci U S A. 1972; 69:1384–6.

17. Meyer K, Palmer JW. The polysaccharide of the vitreous humor. J Biol Chem. 1934; 107:629–34.

18. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem J. 1989; 258:919–22.

19. Ghosh K, Ren XD, Shu XZ, Prestwich GD, Clark RA. Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fibroblast responses critical for wound healing. Tissue Eng. 2006; 12:601–13.

20. Voinchet V, Vasseur P, Kern J. Efficacy and safety of hyaluronic acid in the management of acute wounds. Am J Clin Dermatol. 2006; 7:353–7.

21. Nolan A, Baillie C, Badminton J, Rudralingham M, Seymour RA. The efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration. J Oral Pathol Med. 2006; 35:461–5.

22. LeBeouf RD, Gregg R, Weigel PH, Fuller GM. Effects of hyaluronic acid and other glycosaminoglycans on fibrin polymer formation. Biochemistry. 1987; 26:6052–7.

23. Wheeler JC, Woods JA, Cox MJ, Cantrell RW, Watkins FH, Edlich RF. Evolution of hydrogel polymers as contact lenses, surface coatings, dressings, and drug delivery systems. J Long Term Eff Med Implants. 1996; 6:207–17.

24. Jaffe BM. The role of prostaglandins, thromboxane, and leukotrienes in surgery. Sabiston DC, editor. Textbook of surgery: the biological basis of modern surgical practice. 14th ed.Philadelphia: WB Saunders;1991. p. 465–9.

25. Davidson EM, Rae SA, Smith MJ. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis. 1983; 42:677–9.

26. Smith WL, Meade EA, Dewitt DL. Interaction of PGH synthase isozymes-1 and -2 with nonsteroidal anti-inflammatory drugs. Adv Exp Med Biol. 1997; 400A:189–96.